Rentschler Biopharma and Coriolis Pharma collaborate to offer integrated biopharma solutions
Collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chain
12 Dec 2025
Rentschler Biopharma and Coriolis Pharma have announced a strategic collaboration, that will offer clients seamless, end-to-end solutions from early formulation through to commercial manufacturing, combining their complementary expertise to accelerate a product’s path to market.
Coriolis Pharma brings a unique combination of in silico and wet lab formulation and drug product development expertise, scientific depth, and advanced analytical capabilities to this collaboration. With a legacy of scientific excellence and commitment to innovation, Coriolis supports every drug development phase from R&D to GMP.
Rentschler Biopharma brings extensive experience in bioprocess development and manufacturing for multiple biotherapeutics, backed by a strong track record of reliability and quality. With a long-standing commitment to client-centric solutions, the company provides robust support from process development through to commercial supply.
This collaboration responds to the evolving needs of the biologics market, as increasing complexity in modalities and regulatory expectations drive demand for integrated, science-driven solutions. Clients will benefit from a unified interface and aligned project teams, reducing tech transfer risks and enabling faster progression from early development to clinical and commercial stages.
Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma, said, “This marks an important step for both our organizations and for our global clients, and their patients. Coriolis Pharma shares our focus on technical excellence, reliability, as well as our client-centric approach. By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side, and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster.”
Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma, added, “At Coriolis, we believe that scientific excellence, client-focused innovation, and strong partnerships are key to advancing complex biopharmaceutical programs efficiently and reliably. With Rentschler Biopharma, we have a trusted partner whose process development and manufacturing expertise ideally complements our deep understanding of formulation development and analytical services. Together, we can provide clients with connected, science-driven solutions that help them move their projects forward towards success.”